SCHEMBL607944

SCHEMBL607944

FC(F)(F)c1ccc(-c2ccc3[nH]c4ccccc4c3c2)cc1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 13/20 0.75
AHR P35869 1/20 0.50
CHUK O15111 1/20 0.49
TDO2 P48775 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GPR3 P46089 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GABRA1 P14867 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA5 P31644 1/20 0.46
GABRA3 P34903 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRA4 P48169 1/20 0.46
GABRA6 Q16445 1/20 0.46
BCHE P06276 1/20 0.45
CNR1 P21554 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL262857 0.91 KIF11 (0.63) KIF11AHRCHUKTDO2GABRA1
SCHEMBL263400 0.89 KIF11 (0.60) KIF11AHRCHUKTDO2GABRA1
SCHEMBL19967918 0.87 KIF11 (0.70) KIF11CHUKGABRA1GABRG2GABRB3
SCHEMBL4130017 0.86 KIF11 (1.00) KIF11AHRCHUKALDH1A1GPR3
SCHEMBL30799378 0.86 AHR (0.67) KIF11AHRALDH1A1GPR3HSD17B10
SCHEMBL19510163 0.86 AHR (0.67) KIF11AHRALDH1A1GPR3HSD17B10
SCHEMBL25012836 0.84 KIF11 (0.70) KIF11CHUK
SCHEMBL670060 0.84 AHR (0.70) KIF11AHRALDH1A1GPR3HSD17B10
SCHEMBL16127349 0.84 AHR (0.70) KIF11AHRALDH1A1GPR3HSD17B10
SCHEMBL29511649 0.84 AHR (0.70) KIF11AHRALDH1A1GPR3HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP disclosed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD KIF11 1787/4885AHR 476/4885CHUK 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.